PortfoliosLab logoPortfoliosLab logo
RCUS vs. ABCL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

RCUS vs. ABCL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcus Biosciences, Inc. (RCUS) and AbCellera Biologics Inc. (ABCL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RCUS achieves a 18.30% return, which is significantly lower than ABCL's 66.96% return.


RCUS

1D
-0.21%
1M
-7.06%
6M
33.98%
YTD
18.30%
1Y
207.75%
3Y*
13.05%
5Y*
-2.14%
10Y*
ALL TIME*
4.18%

ABCL

1D
0.35%
1M
-29.59%
6M
57.73%
YTD
66.96%
1Y
34.67%
3Y*
-7.74%
5Y*
-17.75%
10Y*
ALL TIME*
-34.32%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$27.22M$36.48M$44.45M
$32.55M$29.46M$32.96M

RCUS vs. ABCL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
RCUS
Arcus Biosciences, Inc.
18.30%60.04%-22.04%-7.64%-48.90%55.89%-12.18%
ABCL
AbCellera Biologics Inc.
66.96%16.72%-48.69%-43.63%-29.16%-64.46%-34.03%

Correlation

The correlation between RCUS and ABCL is 0.45, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.45

Correlation (3Y)
Balances recent behavior with more history.

0.41

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.40

Correlation (All Time)
Calculated using the full available price history since Dec 11, 2020

0.36

Fundamentals

Market Cap

RCUS:

$3.55B

ABCL:

$1.74B

EPS

RCUS:

-$3.26

ABCL:

-$0.48

PS Ratio

RCUS:

13.51

ABCL:

21.64

PB Ratio

RCUS:

6.75

ABCL:

1.84

Total Revenue (TTM)

RCUS:

$236.00M

ABCL:

$79.21M

Gross Profit (TTM)

RCUS:

$214.00M

ABCL:

$70.89M

EBITDA (TTM)

RCUS:

-$341.00M

ABCL:

-$166.07M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RCUS vs. ABCL — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

RCUS
RCUS Risk / Return Rank: 9797
Overall Rank
RCUS Sharpe Ratio Rank: 9898
Sharpe Ratio Rank
RCUS Sortino Ratio Rank: 9595
Sortino Ratio Rank
RCUS Omega Ratio Rank: 9494
Omega Ratio Rank
RCUS Calmar Ratio Rank: 9898
Calmar Ratio Rank
RCUS Martin Ratio Rank: 9797
Martin Ratio Rank

ABCL
ABCL Risk / Return Rank: 5858
Overall Rank
ABCL Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
ABCL Sortino Ratio Rank: 6161
Sortino Ratio Rank
ABCL Omega Ratio Rank: 5858
Omega Ratio Rank
ABCL Calmar Ratio Rank: 5757
Calmar Ratio Rank
ABCL Martin Ratio Rank: 5656
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

RCUS vs. ABCL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcus Biosciences, Inc. (RCUS) and AbCellera Biologics Inc. (ABCL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


RCUSABCLDifference
Sharpe ratioReturn per unit of total volatility

+3.04

Sortino ratioReturn per unit of downside risk

+2.37

Omega ratioGain probability vs. loss probability

1.44

1.12

+0.32

Calmar ratioReturn relative to maximum drawdown

7.57

0.51

+7.06

Martin ratioReturn relative to average drawdown

19.27

0.91

+18.36

RCUS vs. ABCL - Sharpe Ratio Comparison

The current RCUS Sharpe Ratio is 3.40, which is higher than the ABCL Sharpe Ratio of 0.36. The chart below compares the historical Sharpe Ratios of RCUS and ABCL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

RCUS vs. ABCL - Drawdown Comparison

The maximum RCUS drawdown since its inception was -85.83%, smaller than the maximum ABCL drawdown of -96.84%. Use the drawdown chart below to compare losses from any high point for RCUS and ABCL.


Loading charts...

Drawdown Indicators


RCUSABCLDifference

Max Drawdown

Largest peak-to-trough decline

-85.83%

-96.84%

+11.01%

Max Drawdown (1Y)

Largest decline over 1 year

-27.78%

-54.94%

+27.16%

Max Drawdown (3Y)

Largest decline over 3 years

-70.17%

-68.05%

-2.12%

Max Drawdown (5Y)

Largest decline over 5 years

-85.83%

-90.96%

+5.13%

Current Drawdown

Current decline from peak

-41.84%

-90.64%

+48.80%

Average Drawdown

Average peak-to-trough decline

-48.21%

-84.26%

+36.05%

Ulcer Index

Depth and duration of drawdowns from previous peaks

10.89%

30.52%

-19.63%

Volatility

RCUS vs. ABCL - Volatility Comparison

The current volatility for Arcus Biosciences, Inc. (RCUS) is 14.32%, while AbCellera Biologics Inc. (ABCL) has a volatility of 22.72%. This indicates that RCUS experiences smaller price fluctuations and is considered to be less risky than ABCL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RCUSABCLDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.32%

22.72%

-8.40%

Volatility (6M)

Calculated over the trailing 6-month period

43.30%

58.57%

-15.27%

Volatility (1Y)

Calculated over the trailing 1-year period

61.98%

77.27%

-15.29%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

67.10%

67.67%

-0.57%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

76.22%

70.72%

+5.50%

Dividends

RCUS vs. ABCL - Dividend Comparison

Neither RCUS nor ABCL has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

RCUS vs. ABCL - Financials Comparison

This section allows you to compare key financial metrics between Arcus Biosciences, Inc. and AbCellera Biologics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


RCUS and ABCL have a correlation of 0.45, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ABCL has higher volatility (22.72%) compared to RCUS (14.32%). In terms of maximum drawdown, RCUS dropped -85.83% vs ABCL's -96.84%.

RCUS currently has the higher Sharpe Ratio (3.40 vs 0.36), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RCUS and ABCL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer